此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

SweetSpot - 非营养性甜味剂对健康的影响

2026年11月5日 更新者:Monica Mars、Wageningen University

SweetSpot - 非营养性甜味剂对健康成人血糖调节、肠道微生物组及肠道激素分泌的影响:一项完全控制的交叉干预研究

The aim of the study is to investigate the effect of non-nutritive sweeteners on glucose regulation. Secondary objectives are to investigate the effect of NNS on gut microbiome, gut hormone secretion, sweet taste sensitivity and preference, and the excretion of NNS in urine.

研究概览

详细说明

Sugar intake has increased over the years, simultaneously with the prevalence of overweight and obesity. To decrease sugar intake, consumption of non-nutritive sweeteners (NNS) has increased and opinions on its use remain divided. A fully controlled dietary intervention using a NNS mixture and dose that is similar to real-life intake, is therefore necessary to advance our understanding of the potential effects of NNS on glucose regulation, gut microbiome, and gut hormone secretion under real-life conditions.

The aim of this study is to investigate the effect of non-nutritive sweeteners on glucose regulation. Secondary objectives are to investigate the effect of NNS on gut microbiome, gut hormone secretion, sweet taste sensitivity and preference, and the excretion of NNS in urine.

To do this, a single blind, fully controlled dietary intervention with a cross-over design will be performed. The study will consist of 2x8 weeks of intervention, with a washout of > 6 weeks in between. The study population will be 60 healthy adults aged 45-79, with a BMI between 20-35 kg/m2.

The study will consist of a fully controlled diet of two 8-week intervention periods (2 weeks run-in + 6 weeks intervention). The diets differ in the presence of non-nutritive sweeteners (NNS): NNS-diet versus non-NNS diet, where additional NNS are added to the NNS-diet.

The primary outcome measure will be the within person difference in blood glucose incremental area under the curve following a 75 g glucose tolerance test between the NNS diet and the non-NNS diet. Secondary outcome measures are the effect of NNS on Matsuda index, insulin response, blood lipid profile, and gut hormone secretion will be determined. The effect of NNS on small- and large intestinal microbiome will be investigated by a change in composition, functionality, and short chain fatty acid content. The effect of NNS on sweet taste sensitivity, preference, and liking will be investigated, as well as the excretion of NNS in urine and saliva.

The total time invested by participants is around 85 hours. Participants are restricted for 16 weeks in their eating habits, since they follow a fully controlled diet prepared by the research facility. Participants will visit the research facility in total 38 times. In total, ~ 603 mL of blood will be drawn by experienced nurses over the entire RCT (>6 month period). During DEXA scans, participants will receive a total of about 0.006 mSv of radiation.

Invasive measurements that participants can experience as burden are collection of faecal and urine samples, and finding back the Simba capsules in the stool. Non-invasive measurements for participants are wearing the CGM, wearing the ActiGraph, consuming the blue cakes, and performing sensory tests.

研究类型

介入性

注册 (估计的)

60

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Gelderland
      • Wageningen、Gelderland、荷兰、6708WG
        • Wageningen University & Research

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

45年 至 79年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age 45-79 years;
  • BMI of 20-35 kg/m2;
  • Having veins suitable for placement of a venflon catheter.

Exclusion Criteria:

  • Diseases or prior surgeries affecting the stomach, liver, kidneys or intestines (allowed i.e. appendectomy);
  • Cardiovascular diseases (e.g. heart failure) or cancer (e.g. non-invasive skin cancer allowed);
  • Diagnosed with type 1 or type 2 diabetes;
  • Drug treated thyroid diseases (well substituted hypothyroidism is allowed for inclusion);
  • HbA1c level >6.5% (>48 mmol/mol), as measured during the screening visit;
  • Anaemia defined as Hb concentrations <8.5 mmol/L for men and <7.5 mmol/L for women via finger prick;
  • Regular use of/receiving medication interfering with research outcomes (as judged by research physician), such as use of glucose lowering drugs, insulin, or use of medication that impacts the gastro-intestinal system;
  • Use of antibiotics over the last 3 months before study start;
  • Donated blood within 2 months prior to the screening;
  • Food allergies, intolerances (including lactose/gluten intolerance) for products used in the study design and/or dietary restrictions interfering with the study (including special diets and eating disorders);
  • Followed a diet that can interfere with the study outcomes within 1 month prior to the screening (e.g. ketogenic, sugar free, carbohydrate free);
  • Not willing to eat all products in the study diet, including eggs and dairy. Vegetarian is possible;
  • Not willing to consume non-nutritive sweeteners;
  • Not willing to quit the use of supplements that can interfere with the study outcomes (e.g. pre- or probiotics).
  • Intention to change the intensity of exercise during the study period or planning to join a intensive sport event (e.g. marathon or triathlon);
  • Intention to lose or gain weight;
  • Working night shifts regularly;
  • Smoking regularly
  • Use of soft and/or hard drugs (cannabis included);
  • Abuse of alcohol (defined as >14 glasses (women) or >21 glasses (men) of alcoholic beverages per week);
  • Being pregnant or lactating or planning to become pregnant;
  • Inability to understand study information and/or communicate with staff;
  • Participation in another study that involves an intervention within two months prior to the intervention;
  • Working or doing a thesis/internship at the division of Human Nutrition & Health, or the Food, Health & Consumer Research group of Wageningen Food & Biobased Research.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
其他:NNS / no-NNS

In this arm, participants will first receive the NNS diet, and the no-NNS diet in the second study period.

Fully controlled diet with added mixture of non-nutritive sweeteners. The mixture consist of 6 different non-nutritive sweeteners: acesulfame-K, aspartame, cyclamate, saccharin, sucralose, and rebaudioside A (stevia).

Fully controlled diet without any non-nutritive sweeteners added.

其他:No-NNS / NNS

In this arm, participants will first receive the no-NNS diet, and the NNS diet in the second study period.

Fully controlled diet with added mixture of non-nutritive sweeteners. The mixture consist of 6 different non-nutritive sweeteners: acesulfame-K, aspartame, cyclamate, saccharin, sucralose, and rebaudioside A (stevia).

Fully controlled diet without any non-nutritive sweeteners added.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Difference in change in 2h iAUC glucose after 6 weeks between the intervention and the control.
大体时间:Week 2 and week 8 in both intervention periods (4 times in total)

The primary outcome measure is the difference in change in iAUC of blood glucose levels following a 2-hour oral glucose tolerance test (OGTT) after six weeks between the intervention period and the control period.

Week 2 and week 8 in both intervention periods (4 times in total)

次要结果测量

结果测量
措施说明
大体时间
Matsuda index
大体时间:Week 2 and week 8 in both intervention periods (4 times in total)

Matsuda index after an OGTT

Week 2 and week 8 in both intervention periods (4 times in total)
Fasting blood glucose
大体时间:Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Fasting blood glucose

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
Fasting blood insulin
大体时间:Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Fasting blood insulin

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
Postprandial insulin response
大体时间:Week 2 and 8 in both intervention periods (4 times in total).

2-hour iAUC blood insulin during OGTT

Week 2 and 8 in both intervention periods (4 times in total).
Postprandial glucose response after a breakfast
大体时间:Week 7 in both study periods (2 times in total)

Postprandial blood glucose responses (PPGR) following specific meals measured by CGM.

Week 7 in both study periods (2 times in total)
Blood lipid profile
大体时间:Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

All circulating blood lipids, including all cholesterol types, triglycerides, and free fatty acids (FFAs).

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
Gut microbiota composition
大体时间:Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.

Microbiota composition in faeces

Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
Gut microbiota function
大体时间:Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.

Microbiota functionality measured in faeces

Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
Microbial metabolites
大体时间:Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.

Microbial metabolites measured in faeces

Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
Small intestinal microbiota composition
大体时间:Week 7 of both intervention periods (2 times in total).

Microbiota composition of the small intestine measured with Simba Capsules

Week 7 of both intervention periods (2 times in total).
Gastro-intestinal transit time
大体时间:Baseline & week 7 of both intervention periods (3 times in total).

Gastro-intestinal transit time measured with blue muffins.

Baseline & week 7 of both intervention periods (3 times in total).
Oral microbiome composition & function
大体时间:Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Oral microbiome composition & function measured in saliva

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
Postprandial GLP-1 secretion
大体时间:Week 2 and 8 of both intervention periods (4 times in total).

3-hour AUC of GLP-1 during an OGTT.

Week 2 and 8 of both intervention periods (4 times in total).
Postprandial GIP secretion
大体时间:Week 2 and 8 of both intervention periods (4 times in total).

3-hour AUC of GIP during an OGTT.

Week 2 and 8 of both intervention periods (4 times in total).
Sweetness-liker phenotype
大体时间:Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Sweetness-liker phenotype, with the sweetness liker test.

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
Sweetness preference & liking
大体时间:Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Sweetness preference & liking measured on a rank-rating scale. Preference will be determined using the categorical values from the rank-rating scale (1-5), and liking will be determined using the continuous values from the rank-rating scale (0-100).

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
Sweet taste sensitivity
大体时间:Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Sweet taste sensitivity measured on a 100mm Visual Analogue Scale. A higher score for all solutions indicates a higher sweet taste sensitivity.

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
Excretion of NNS in urine
大体时间:Baseline, week 2 and week 8 in intervention period 1, and every two weeks in intervention period 2 (7 times in total).

Excretion of NNS in urine

Baseline, week 2 and week 8 in intervention period 1, and every two weeks in intervention period 2 (7 times in total).
Excretion of NNS in saliva
大体时间:Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Excretion of NNS in saliva

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

其他结果措施

结果测量
措施说明
大体时间
Anthropometrics
大体时间:Baseline

Measured as weight (kg), height (m), waist circumference (cm), and hip circumference (cm). Weight and height will be combined to report BMI in kg/m^2.

Baseline
Body composition
大体时间:Baseline & week 8 of both intervention periods (3 times in total).

Body composition as measured by DEXA (Dual Energy X-ray Absorptiometry).

Baseline & week 8 of both intervention periods (3 times in total).
Habitual food intake
大体时间:Baseline

Habitual dietary intake assessment with a food frequency questionnaire (FFQ).

Baseline
Physical activity level
大体时间:Baseline.

Physical activity level by the Short Questionnaire to Assess Health-enhancing physical activity (SQUASH).

Baseline.
Habitual NNS consumption
大体时间:Baseline

Habitual NNS consumption by questionnaire

Baseline
Gastro-intestinal symptoms
大体时间:Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.

Gastro-intestinal symptoms by GSRS questionnaire.

Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.
Satiety
大体时间:Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.

Satiety questionnaire, adapted from the Control of Eating Questionnaire.

Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.
Genetic variation
大体时间:Baseline

Single Nucleotide Polymorphisms (SNPs) in genes relevant collected using buffycoat.

Baseline
Taste function
大体时间:Baseline

Measure the ability to recognize the basic tastes in different concentrations, assessed with validated Taste Strips.

Baseline

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年2月23日

初级完成 (估计的)

2027年3月26日

研究完成 (估计的)

2027年3月26日

研究注册日期

首次提交

2026年1月13日

首先提交符合 QC 标准的

2026年1月13日

首次发布 (实际的)

2026年1月23日

研究记录更新

最后更新发布 (实际的)

2026年11月6日

上次提交的符合 QC 标准的更新

2026年11月5日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅